deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT00954993

Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)

A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Following Administration of MK-7009 in Hepatitis C Infected Patients

Sponsor: Merck Sharp & Dohme LLC

Conditions Chronic Hepatitis C Infection
Interventions Vaniprevir
Updated 14 times since 2017 Last updated: Sep 21, 2018 Started: Jan 13, 2010 Primary completion: Mar 4, 2011 Completion: Mar 4, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was stopped for business and program changes. At no time was the safety of any participants at risk.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Other Chronic Hepatitis C Infection trials with similar outcome

Browse all Chronic Hepatitis C Infection trials

This PHASE1 trial investigates Chronic Hepatitis C Infection and is currently terminated or withdrawn. Merck Sharp & Dohme LLC leads this study, which shows 14 recorded versions since 2010 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~May 2018 · 9 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Nov 2020 · 24 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshot~Jun 2022 – ~Dec 2022 · 6 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 21 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE1

  5. Jun 2022 — Dec 2022 [monthly]

    Terminated PHASE1

▶ Show 9 earlier versions

  1. Dec 2021 — Jun 2022 [monthly]

    Terminated PHASE1

  2. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1

  3. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE1

  4. Nov 2018 — Nov 2020 [monthly]

    Terminated PHASE1

  5. Jun 2018 — Nov 2018 [monthly]

    Terminated PHASE1

  6. May 2018 — Jun 2018 [monthly]

    Terminated PHASE1

  7. Aug 2017 — May 2018 [monthly]

    Terminated PHASE1

  8. Feb 2017 — Aug 2017 [monthly]

    Terminated PHASE1

  9. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.